-
1
-
-
78650610154
-
Intensive blood-pressure control in hypertensive chronic kidney disease
-
Appel LJ,Wright JT, Jr, Greene T et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363: 918-929
-
(2010)
N Engl J Med
, vol.363
, pp. 918-929
-
-
Appel, L.J.1
Wright, J.T.2
Greene, T.3
-
2
-
-
79958817916
-
Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes A collaborative meta-analysis of general and high-risk population cohorts
-
Gansevoort RT,Matsushita K, van der VeldeMet al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 2011; 80: 93-104
-
(2011)
Kidney Int
, vol.80
, pp. 93-104
-
-
Gansevoort, R.T.1
Matsushita, K.2
Van Der Velde, M.3
-
3
-
-
79957827666
-
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease A collaborative meta-analysis of kidney disease population cohorts
-
Astor BC, Matsushita K, Gansevoort RT et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int 2011; 79: 1331-1340
-
(2011)
Kidney Int
, vol.79
, pp. 1331-1340
-
-
Astor, B.C.1
Matsushita, K.2
Gansevoort, R.T.3
-
4
-
-
85047697782
-
Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease
-
Gansevoort RT, de Zeeuw D, de Jong PE. Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease. Nephrol Dial Transplant 1995; 10: 497-504
-
(1995)
Nephrol Dial Transplant
, vol.10
, pp. 497-504
-
-
Gansevoort, R.T.1
De Zeeuw, D.2
De Jong, P.E.3
-
5
-
-
0028887054
-
Antiproteinuric effect of blood-pressure-lowering agents: A meta-analysis of comparative trials
-
Gansevoort RT, Sluiter WJ, HemmelderMHet al. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995; 10: 1963-1974
-
(1995)
Nephrol Dial Transplant
, vol.10
, pp. 1963-1974
-
-
Gansevoort, R.T.1
Sluiter, W.J.2
Hemmelder, M.H.3
-
6
-
-
46049091172
-
Effects of strict blood pressure control by a long-acting calcium channel blocker on brain natriuretic peptide and urinary albumin excretion rate in Japanese hypertensive patients
-
Uno H, Ishikawa J, Hoshide S et al. Effects of strict blood pressure control by a long-acting calcium channel blocker on brain natriuretic peptide and urinary albumin excretion rate in Japanese hypertensive patients. Hypertens Res 2008; 31: 887-896
-
(2008)
Hypertens Res
, vol.31
, pp. 887-896
-
-
Uno, H.1
Ishikawa, J.2
Hoshide, S.3
-
7
-
-
0028838569
-
Blood pressure control, proteinuria, and the progression of renal disease the modification of diet in renal disease study
-
Peterson JC, Adler S, Burkart JM et al. Blood pressure control, proteinuria, and the progression of renal disease. the modification of diet in renal disease study. Ann Intern Med 1995; 123: 754-762
-
(1995)
Ann Intern Med
, vol.123
, pp. 754-762
-
-
Peterson, J.C.1
Adler, S.2
Burkart, J.M.3
-
8
-
-
0030979322
-
Predictors of the progression of renal disease in the modification of diet in renal disease study
-
Hunsicker LG, Adler S, Caggiula A et al. Predictors of the progression of renal disease in the modification of diet in renal disease study. Kidney Int 1997; 51: 1908-1919
-
(1997)
Kidney Int
, vol.51
, pp. 1908-1919
-
-
Hunsicker, L.G.1
Adler, S.2
Caggiula, A.3
-
9
-
-
0035902622
-
Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease A meta-analysis of patient-level data
-
Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87
-
(2001)
Ann Intern Med
, vol.135
, pp. 73-87
-
-
Jafar, T.H.1
Schmid, C.H.2
Landa, M.3
-
10
-
-
65249111029
-
Lowering blood pressure reduces renal events in type 2 diabetes
-
de Galan BE, Perkovic V, Ninomiya T et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009; 20: 883-892
-
(2009)
J Am Soc Nephrol
, vol.20
, pp. 883-892
-
-
De Galan, B.E.1
Perkovic, V.2
Ninomiya, T.3
-
11
-
-
84880922135
-
Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention
-
Gansevoort RT, Correa-Rotter R, Hemmelgarn BR et al. Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention. Lancet 2013; 382: 339-352
-
(2013)
Lancet
, vol.382
, pp. 339-352
-
-
Gansevoort, R.T.1
Correa-Rotter, R.2
Hemmelgarn, B.R.3
-
12
-
-
0028725184
-
Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease
-
Chapman AB, Johnson AM, Gabow PA et al. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1994; 5: 1349-1354
-
(1994)
J Am Soc Nephrol
, vol.5
, pp. 1349-1354
-
-
Chapman, A.B.1
Johnson, A.M.2
Gabow, P.A.3
-
13
-
-
0031667544
-
Factors relating to urinary protein excretion in children with autosomal dominant polycystic kidney disease
-
Sharp C, Johnson A, Gabow P. Factors relating to urinary protein excretion in children with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1998; 9: 1908-1914
-
(1998)
J Am Soc Nephrol
, vol.9
, pp. 1908-1914
-
-
Sharp, C.1
Johnson, A.2
Gabow, P.3
-
14
-
-
0031728322
-
Microalbuminuria in normotensive patients with autosomal-dominant polycystic kidney disease
-
Martinez-Vea A, Gutierrez C, Bardaji A et al. Microalbuminuria in normotensive patients with autosomal-dominant polycystic kidney disease. Scand J Urol Nephrol 1998; 32: 356-359
-
(1998)
Scand J Urol Nephrol
, vol.32
, pp. 356-359
-
-
Martinez-Vea, A.1
Gutierrez, C.2
Bardaji, A.3
-
15
-
-
77958456505
-
Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: A cross-sectional analysis
-
Meijer E, Boertien WE, Nauta FL et al. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis. Am J Kidney Dis 2010; 56: 883-895
-
(2010)
Am J Kidney Dis
, vol.56
, pp. 883-895
-
-
Meijer, E.1
Boertien, W.E.2
Nauta, F.L.3
-
16
-
-
77953305179
-
Early renal abnormalities in autosomal dominant polycystic kidney disease
-
Meijer E, Rook M, Tent H et al. Early renal abnormalities in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2010; 5: 1091-1098
-
(2010)
Clin J Am Soc Nephrol
, vol.5
, pp. 1091-1098
-
-
Meijer, E.1
Rook, M.2
Tent, H.3
-
17
-
-
32644459917
-
A comparative study of three kidney biomarker tests in autosomal-dominant polycystic kidney disease
-
Casal JA, Hermida J, Lens XM et al. A comparative study of three kidney biomarker tests in autosomal-dominant polycystic kidney disease. Kidney Int 2005; 68: 948-954
-
(2005)
Kidney Int
, vol.68
, pp. 948-954
-
-
Casal, J.A.1
Hermida, J.2
Lens, X.M.3
-
18
-
-
79953011165
-
Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease
-
Torres VE, Grantham JJ, Chapman AB et al. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6: 640-647
-
(2011)
Clin J Am Soc Nephrol
, vol.6
, pp. 640-647
-
-
Torres, V.E.1
Grantham, J.J.2
Chapman, A.B.3
-
19
-
-
84871303897
-
Tolvaptan in patients with autosomal dominant polycystic kidney disease
-
Torres VE, Chapman AB, Devuyst O et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367: 2407-2418
-
(2012)
N Engl J Med
, vol.367
, pp. 2407-2418
-
-
Torres, V.E.1
Chapman, A.B.2
Devuyst, O.3
-
20
-
-
79954622171
-
Rationale and design of the TEMPO (tolvaptan efficacy and safety in management of autosomal dominant polycystic kidney disease and its outcomes) 3-4 study
-
Torres VE, Meijer E, Bae KT et al. Rationale and design of the TEMPO (tolvaptan efficacy and safety in management of autosomal dominant polycystic kidney disease and its outcomes) 3-4 study.AmJ Kidney Dis 2011; 57: 692-699
-
(2011)
AmJ Kidney Dis
, vol.57
, pp. 692-699
-
-
Torres, V.E.1
Meijer, E.2
Bae, K.T.3
-
21
-
-
65649142017
-
A new equation to estimate glomerular filtration rate
-
Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612
-
(2009)
Ann Intern Med
, vol.150
, pp. 604-612
-
-
Levey, A.S.1
Stevens, L.A.2
Schmid, C.H.3
-
22
-
-
79959500985
-
Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease
-
Meijer E, Boertien WE, Zietse R et al. Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease. Kidney Blood Press Res 2011; 34: 235-244
-
(2011)
Kidney Blood Press Res
, vol.34
, pp. 235-244
-
-
Meijer, E.1
Boertien, W.E.2
Zietse, R.3
-
23
-
-
0346666698
-
Vasopressin increases urinary albumin excretion in rats and humans: Involvement of V2 receptors and the renin-angiotensin system
-
Bardoux P, Bichet DG, Martin H et al. Vasopressin increases urinary albumin excretion in rats and humans: Involvement of V2 receptors and the renin-angiotensin system. Nephrol Dial Transplant 2003; 18: 497-506
-
(2003)
Nephrol Dial Transplant
, vol.18
, pp. 497-506
-
-
Bardoux, P.1
Bichet, D.G.2
Martin, H.3
-
24
-
-
79960426743
-
Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease
-
IrazabalMV, Torres VE, HoganMCet al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int 2011; 80: 295-301
-
(2011)
Kidney Int
, vol.80
, pp. 295-301
-
-
Irazabal, M.V.1
Torres, V.E.2
Hogan, M.C.3
-
25
-
-
84888646403
-
Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease
-
Boertien WE,Meijer E, de Jong PE et al. Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease. Kidney Int 2013; 84: 1278-1286
-
(2013)
Kidney Int
, vol.84
, pp. 1278-1286
-
-
Boertien, W.E.1
Meijer, E.2
De Jong, P.E.3
-
26
-
-
84930439449
-
Short-term effects of tolvaptan in subjects with ADPKD at various levels of kidney function
-
Boertien WE, Meijer E, de Jong PE et al. Short-term effects of tolvaptan in subjects with ADPKD at various levels of kidney function. Am J Kidney Dis 2015; 65: 833-841
-
(2015)
Am J Kidney Dis
, vol.65
, pp. 833-841
-
-
Boertien, W.E.1
Meijer, E.2
De Jong, P.E.3
-
27
-
-
77950256964
-
Glomerular and proximal tubule cysts as early manifestations of Pkd1 deletion
-
Ahrabi AK, Jouret F, Marbaix E et al. Glomerular and proximal tubule cysts as early manifestations of Pkd1 deletion. Nephrol Dial Transplant 2010; 25: 1067-1078
-
(2010)
Nephrol Dial Transplant
, vol.25
, pp. 1067-1078
-
-
Ahrabi, A.K.1
Jouret, F.2
Marbaix, E.3
|